The NIH is partnering with the U.S. Food and Drug Administration (FDA) and the Defense Advanced Research Projects Agency (DARPA) to advance the field of regulatory science, a specialized research area that aims to improve assessment of experimental therapies, preventives, and diagnostics. The Common Fund’s Regulatory Science program is fostering the development, evaluation and availability of new or improved tools, methods, standards, and applied science that support a better understanding and improved evaluation of product safety, quality, effectiveness, and manufacturing throughout the product life cycle.
During the initial phase of the program, launched in fiscal year 2010, four new research awards in high priority areas of regulatory science were supported. Expansion of the program in FY 2012 focuses on developing new cell-based technologies, called microsystems, to predict more accurately drug safety and efficacy in humans.
- NEW! NIH Director's Blog: If I Only Had a Brain? Tissue Chips Predict Neurotoxicity
- Researchers Create Artificial Organs That Fit In Your Hand (NPR)
- In the New Yorker article: “Of Mice and Micro-Organs.”
- On WXXI News, read and listen to: “Human-on-a-chip” featuring MPS members from the NIH Center for Advancing Translational Sciences.
- In a special supplement to Volume 4 of the journal Stem Cell Research & Therapy.
- Vanderbilt’s neurovascular chip project moves into new phase
National Center for Advancing Translational Sciences (NCATS) site: Tissue Chip for Drug Screening program
Chip is an interactive model that can help you learn about the innovative developments from the Tissue Chip program.
For more information about the Tissue Chip program, watch the new video from the National Center for Advancing Translational Sciences (NCATS).